Essential Tremor and Parkinson’s Disease: Exploring the Relationship by Tarakad, Arjun & Jankovic, Joseph
Reviews
Essential Tremor and Parkinson’s Disease: Exploring the Relationship
Arjun Tarakad & Joseph Jankovic
*
Parkinson’s Disease Center and Movement Disorders Clinic, Baylor College of Medicine Houston, TX, USA
Abstract
Background: There is longstanding controversy surrounding the possible link between essential tremor (ET) and Parkinson’s disease (PD). Inconsistent and
unreliable diagnostic criteria may in part account for some of the difficulties in defining the relationship between these two common movement disorders.
Methods: References for this systematic review were identified using PubMed with the search terms ‘‘essential tremor’’ AND ‘‘Parkinson’s disease’’ with articles
published in English between 1960 and September 2018 included.
Results: In this review we provide evidence that some patients diagnosed with ET have an increased risk of developing PD years or decades after onset of action
tremor. There are several still unresolved questions about the link between the two disorders including lack of verifiable diagnostic criteria for the two disorders and
marked overlap in phenomenology. Here we review clinical, epidemiologic, imaging, pathologic, and genetic studies that address the ET–PD relationship. Several
lines of evidence support the association between ET and PD, including overlapping motor and non-motor features, relatively high prevalence of rapid eye
movement sleep behavior disorder (26–43%) in ET patients, increased prevalence of PD in patients with longstanding antecedent ET, increased prevalence of ET in
family members of patients with PD, and the presence of Lewy bodies in the brains of some ET patients (15–24%).
Discussion: There is a substantial body of evidence supporting the association between ET and PD within at least a subset of patients, although the nature and
possible pathogenic mechanisms of the relationship are not well understood.
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Introduction
There has been a longstanding debate among movement disorder
specialists as to whether or not essential tremor (ET) confers a greater
risk of developing, or is otherwise linked to, Parkinson’s disease (PD).
This topic has been addressed in the past,1–5 but it is worth revisiting it
in view of recently published data related to this subject, including new
diagnostic criteria for ET and PD, and additional studies in imaging,
epidemiology, pathology, and genetics.
Methods
References for this systematic review were identified using PubMed
with the search terms ‘‘essential tremor’’ AND ‘‘Parkinson’s disease’’ in
September 2018, which resulted in 1,180 articles. Articles published
in English between 1960 and September 2018 comparing ET and PD
were reviewed in further depth. Additional articles were identified
through a review of the authors’ own files.
Results and Discussion
Diagnosis
First introduced by Burresi (Italy) in 1874 to describe patients with
action (postural and kinetic) tremor in the hands and no other neuro-
logic signs, subsequent descriptions have expanded the ET phenotype
to include involvement of head, voice, and legs and other movement
disorders (e.g., dystonia, myoclonus, parkinsonism, ataxia), response to
alcohol and beta-blockers, and hereditary nature.6,7 This gave rise to
numerous debates as to whether ET is a single entity or a syndrome.8–14
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In the recently published Classification of Tremors by the Task Force
on Tremor of the International Parkinson and Movement Disorder
Society (IPMDS), ET has been defined in Axis I as a syndrome and
divided into ‘‘ET’’ and ‘‘ET plus.’’15 According to this classification
ET is an isolated action tremor involving both upper limbs, at least
3 years in duration, with or without tremor in other locations, and
in the absence of other neurological signs such as dystonia, ataxia,
or parkinsonism. Although the statement acknowledges that patients
frequently have a family history and alcohol may improve the tremor,
the authors concluded that these clinical features are not consistent
enough to be included in the definition of ET. ET plus is defined as
tremor with the characteristics of ET and additional neurologic signs
of uncertain significance such as impaired tandem gait, questionable
dystonic posturing, memory impairment, or other mild neurologic
signs of unknown significance that do not suffice to make an additional
syndrome classification or diagnosis. Exclusionary criteria of ET and
ET plus require ruling out enhanced physiological tremor, isolated
focal tremors (head or voice), orthostatic tremor with frequency greater
than 12 Hz, task- and position-specific tremors, and sudden onset and
other features suggestive of functional (psychogenic tremor). Complicating
the distinction between ET and ET plus is the potential for symptoms
to evolve over time (such as with the development of parkinsonism
or cerebellar symptoms) that necessitates a change in the patient’s
diagnosis from ET to ET plus, provided they do not meet criteria for
an alternative neurologic diagnosis. Indeed, the consensus statement
acknowledges that patients with longstanding ET may ultimately
develop other neurologic conditions such as dystonia or PD and that
‘‘ET is a syndrome that may evolve into another tremor syndrome.’’
Thus patients with longstanding ET who later develop a PD pheno-
type would be referred to as PD with ‘‘antecedent ET.’’ It should be
noted that there have been dissenting opinions expressed following the
publication of the consensus statement,7,16 and future revisions are likely.
Besides the evolution of ET to another or additional movement
disorder, the presence of multiple or mixed phenotypes (of ET, PD,
and dystonia) within family members of patients with ET also presents
a challenge in defining ET. For example in three of our four kindreds
examined in detail, in which several members had ET as defined
by the presence of bilateral postural tremor involving the hands or
forearms that was visible and persistent, lasting longer than 5 years,
and without any other additional neurologic symptoms, other members
of the family had additional movement disorders, such as dystonia
and parkinsonism.17 Although no gene mutations have been identified
in these families, we hypothesized that the various affected family
members had different phenotype of the same genetic disorder. Finding
specific and sensitive genetic and other biomarkers for ET would
clearly help in addressing this important issue of different phenotypes
despite the same etiology versus phenocopies associated with different
etiologies.
The gold standard for the diagnosis of PD is based on autopsy
findings, with neuronal loss in the substantia nigra and the presence
of Lewy bodies and Lewy neurites as the pathologic hallmarks of the
disease.18 However, the pathology-based definition of PD has been
challenged and some have proposed that, similar to ET, PD should
also be considered a syndrome as it can present in the setting of dif-
ferent motor and non-motor phenomenologies, heterogeneous patho-
logical findings, and with increasingly recognized genetic etiologies.
Clinically, PD is characterized by a wide variety of motor symptoms
(bradykinesia, rigidity, tremor, gait disturbances, and dystonia among
others), and non-motor symptoms (including mood disorders, anosmia,
rapid eye movement sleep behavior disorder (RBD), and autonomic
dysfunction).19–21 Some of these non-motor features such as mood
disorders and RBD may also occur at a higher frequency in ET
patients than controls (as will be discussed later).22,23 Historically, the
UK Brain Bank criteria have been most widely used in clinically
diagnosing PD, defined as the presence of bradykinesia with at least
one additional feature of muscular rigidity, 4–6 Hz rest tremor, or
postural instability; and the absence of exclusionary features (including
strokes with stepwise progression of parkinsonism, head injury, neuroleptic
treatment at symptom onset, or atypical parkinsonism features), which
would suggest an alternative diagnosis.24 The 2015 MDS clinical diag-
nostic criteria defined parkinsonism as the presence of bradykinesia
with either rest tremor or rigidity, with ‘‘clinically established PD’’
additionally requiring at least two supportive features (which include
a clear and dramatic beneficial response to dopaminergic therapy, the
presence of levodopa-induced dyskinesias, rest tremor documented on
clinical examination, or the presence of either olfactory loss or cardiac
sympathetic denervation on metaiodobenzylguanidine scintigraphy)
and no exclusionary criteria or ‘‘red flags.’’25
Although we believe, based on our clinical experience following
longitudinally patients with ET over decades, that a subset of ET
patients has a higher than expected risk for developing PD, we have
tried to interpret the literature related to this topic as objectively as
possible and without specific bias. One of the major areas of disagre-
ement among experts is the diagnosis of the observed clinical entity.
For example, PD patients often present with action tremor prior devel-
oping more overt PD signs.26 Is the postural tremor in these patients
ET or an early presentation of PD? If the latency between onset of
postural tremor and other features of PD is long (e.g., .10 years) it
would be difficult to argue that the postural tremor (in some cases of
childhood onset)2 is an early manifestation of PD. Because it is difficult
to diagnose ET in a patient who already has PD (although the presence
of head, voice, and writing tremor suggests the diagnosis of coexistent
ET), there are no studies to address the possible relationship between
antecedent PD in patients who later develop ET.27 Another challenge
is to determine whether additional symptoms in patients with long-
standing ET, such as the emergence of rest tremor, bradykinesia,
cogwheeling, and postural instability are manifestations of ET plus or
the beginnings of PD. Although DaTscan imaging, if abnormal, may
provide evidence for underlying PD, ultimately only brain autopsy can
answer the question whether the patient has a longstanding but slowly
evolving PD, merely ET with age-related changes, or a separate
syndrome, a combination of both ET and PD. If it is the latter, then
the next question that needs to be addressed is whether the ET–PD
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association is coincidental or pathogenically related. We believe that
the reported data, reviewed below, provides evidence for the latter.
Phenomenology
While ET is characterized by action tremor and PD by rest tremor,
some patients have overlapping features that can present a diagnostic
challenge. PD patients have been noted to have postural tremor of two
phenotypes: 1) a re-emergent postural tremor that appears after a
latency of a few seconds when assuming a horizontal (anti-gravity)
position of the arms and often responds to levodopa, and 2) a postural
tremor without latency that phenomenologically resembles ET.26,28,29
Some ET patients can develop rest tremor, particularly with longer
disease duration.30 In the authors’ personal experience, one of the
most common reasons why ET–PD syndrome may not be recognized
is because the examiner fails to ask the critical question of a patient
with clinically diagnosed PD if they or others ever noted any other
tremor prior to the onset of rest tremor. It is remarkable how often
patients endorse postural or action tremors from relatively early on
in life. Without diligently seeking answer to this critical question one
would never suspect pre-existing (antecedent) ET, though some would
argue this could also represent earlier motor manifestations of PD.
Several physiological studies have provided evidence for overlap
between ET and PD. Both ET and PD show similar impairment in
primary motor cortex excitability in response to paired associative
stimulation.31 Another study of 46 PD patients, 34 ET patients, and
56 controls demonstrated slowed reaction times and slower movement
velocities in ET (and as expected in PD) patients relative to controls.32
Some electrophysiologic studies have also found distinctions between
the two conditions including that the muscle contractions in patients
with rest tremor associated with ET are mainly synchronous whereas
those in PD-related rest tremor are mainly alternating, though these
patterns do not always differentiate the two types of tremor.33,34 While
the cerebellum has been implicated in the pathophysiology of ET,
evidence that the cerebellum is the source of ET has not been sup-
ported by some recent studies that also found that cortical contribution
to PD and ET tremor are similar.35
ET–PD combination
Once patients develop clinical features of PD it is difficult to diag-
nose coexistent ET although there are some clues, such as the presence
of head, voice, and writing tremor; family history of tremor (and/or
alcoholism); and improvement with alcohol, where ET may also be
suspected.2,27 In one study involving 53 ET–PD patients and 150 ET
patients, it was noted that the ET–PD group showed a male predomi-
nance (68%) similar to the 2:1 ratio seen in PD.27 The mean latency
from onset of ET to first sign on neurologic examination of PD was
14¡ 15 years. The mean age at onset of ET symptoms was 51.8 years
with the first clinical symptom of PD at 65.8; 30.8% had a long latency
(.20 years) between onset of ET and onset of PD symptoms. The
more affected side of early tremor correlated with the side later exhi-
biting more parkinsonian signs such as reduced arm swing (78.6% p 5
0.009) bradykinesia (71.4% p 5 0.003), rigidity (56.3% p 5 0.03) and
rest tremor (73.3% p , 0.001).27 This is similar to our findings in
patients with asymmetric, childhood-onset ET.36 One study involving
621 individuals in families with ET identified 22 patients with isolated
PD, 20 of whom (90%) had tremor-dominant PD.37 The predilection
of patients in this population to present with tremor dominant PD over
other subtypes highlights the association of this subtype of PD with ET.
Another study comparing 25 patients with ET–PD to 125 patients with
PD found rest and action tremor to be more prominent in the ET–PD
group, which also had a higher prevalence of tremor in first-degree
relatives.38 Other studies also found a stronger family history of ET in
the ET–PD group than in the isolated PD group.39–41 Together these
studies demonstrate distinct features of the ET–PD phenotype: tremor-
dominant subtype of PD, long duration of tremor before onset of
parkinsonism, presence of cerebellar signs, slow progression, and a
strong family history of tremor (Table 1).
Non-motor symptoms
Non-motor symptoms, while traditionally associated with PD, are
being increasingly recognized as a part of ET. Impaired neuropsycho-
logical performance in ET, particularly in frontal domains such as
executive function, have been noted in several studies.42–45 A large
population-based study from Spain demonstrated a greater degree
of cognitive decline on the 37 item Mini-Mental State Examination
(0.7 points versus 0.11 points p 5 0.03) in 135 ET patients compared
to 2,184 controls,42 with a more recent follow-up suggesting that this
cognitive decline was in a partially overlapping pattern (though to a
lesser degree) to that in PD.43 A study of neuropsychological perfor-
mance between 32 ET and 32 PD patients also demonstrated deficits
in similar areas of cognitive function (particularly with involvement of
the prefrontal cortex) when compared to controls (n5 32).44 In a study
of 23 ET patients, a subset of eight (35%) patients showed impaired
visuomotor control, similar to that seen in PD.46
Mood disturbances and apathy, similar to those in PD, have also been
reported at an increased frequency in ET patients.46–50 This, however,
may not be specific as there are many other disorders associated with
depression and other mood changes.
Sleep disturbances and RBD are well established in PD, often as
prodromal symptoms, but have also been reported at a relatively high
frequency in ET patients. One study using the RBD Screening
Questionnaire (RBDSQ) showed a high frequency of RBD symptoms
(43.5%) in ET patients relative to an estimated 0.5% frequency of
RBD in the general population.47 In another study of 92 ET patients
screened by phone questionnaires, the frequency of RBD was 26.4%.22
In a study of 120 ET patients, 120 controls, and 40 PD patients,
ET patients were found to have intermediate Epworth Sleepiness Scale
scores compared to controls and PD patients.48 Increased daytime
somnolence, as determined by the Epworth Sleepiness Scale, was
found in both ET and PD patients relative to controls (5.75, p5 0.009,
and 6.98, p 5 0.001, respectively versus 2.68).45
Collectively these disturbances in cognition, mood, and sleep suggest
more widespread neurologic involvement in ET with significant overlap
in changes in domains associated with PD. While not symptoms per se,
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other similarities between ET and PD populations include a greater
risk in developing melanoma,49,50 and a decreased risk of in both
conditions among smokers.51–53
Epidemiology
Epidemiologic studies examining a link between ET and PD
have focused either on the co-occurrence of ET and PD, or the
occurrence of ET and/or PD in family members of patients with
either condition.
Co-occurrence of ET and PD. There are no longitudinal prospective
studies of patients with ET to determine the incidence of subsequent
parkinsonism. Furthermore, the question of the nature of parkinsonism
in such patients has not been fully addressed. Do these patients have
ET and later go on to develop PD, have PD with ‘‘antecedent tremor,’’
have parkinsonism related to ET (ET plus), or is the coexistence of
the two disorders purely coincidental, by chance alone? There are
currently no definite answers to these critical questions. There are,
however, several epidemiological studies to support the notion that
combination of ET and parkinsonism is not purely coincidental. In a
population-based study from Spain, six (3%) of 201 patients with ET
developed PD as compared to 0.4% of 3,574 controls, supporting the
notion that ET patients have a higher risk for developing PD.54 In a
study by the Essential Tremor Study Group of 678 patients, 6.1% of
ET patients were found to have PD,55 while in another study involving
130 patients with ET, 25 (20.8%) were noted to have coexistent PD.56
In one large study of 600 patients, a higher occurrence of ET in
PD patients (5.9%) was noted than in healthy controls (0.5%), or
vin ‘‘diseased’’ controls with hemifacial spasm (1%).57 In one study
involving 22 PD patients with a history of childhood-onset ET (before
age 20, mean age at onset 13.8 years), 11 patients (50%) reported
asymmetric childhood ET, with 10 (91%) of these patients reporting
PD symptoms developing on the same side as the more prominent
childhood tremor.36 Lastly, in a retrospective study of 350 ET patients
from the same center, 20.2% were noted to display at least three of the
four cardinal signs of PD.58





Overlapping clinical motor features, e.g. rest tremor, cogwheeling, postural instability26,28–30,58
Slowed reaction times31,32
Preserved olfaction in tremor dominant PD patients with family history of tremor41
Cognitive dysfunction (primarily frontal/executive problems)42–46
Increased frequency of anxiety, depression, and apathy45,47,112,113
Increased frequency of RBD and daytime somnolence22,45,47,48
Emergence of PD after long-standing ET27
PD asymmetry correlating with historical tremor asymmetry and severity27,36
Increased incidence of rest and action tremor in ET–PD group versus PD38
Increased cerebellar signs and more diffuse tremor in ET–PD patients than isolated PD patients39
Increased risk of melanoma in PD and ET49,50
Decreased risk of PD and ET among smokers51–53
Epidemiologic Increased prevalence of PD in ET patients relative to general population54–57
Increased prevalence of ET in family members of PD patients60–65
Increased prevalence of tremor dominant PD in ET families37
Increased family history of tremor in relatives of ET–PD patients than isolated PD patients38,40
Imaging Hyperechogenicity in substantia nigra of ET patients associated with progression to PD68
Reduced striatal dopamine uptake on DaTscan69–71
Pathologic Overlapping cerebellar pathology of changes in climbing fiber density and torpedoes74,75,77,78











Abbreviations: ET, Essential Tremor; PD, Parkinson’s Disease; RBD, Rapid Eye Movement Sleep Behavior Disorder.
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Although genetic factors most likely play a pivotal role in the
development of ET–PD syndrome, other possible explanations for
the increased risk of PD in patients with pre-existing ET have
been offered. For example, some investigators have recently proposed
that beta-blockers used in the treatment of ET may increase the
risk of developing PD. This hypothesis is based on a large registry
study, utilizing data from the Norwegian public health registry (n 5
4 million), which found an association between use of the beta2-
adrenergic agonist salbutamol and the beta2-adrenergic antagonist
propranolol and the risk of developing PD.59 Further studies found
that beta2-adrenergic antagonists may increase alpha-synuclein, the
toxic protein implicated in the pathogenesis of PD, and thus have
detrimental effects on dopaminergic neurons. Although this is an
intriguing hypothesis to explain the relationship between ET and PD,
further studies are needed to further explore this association.
ET and PD in family members
There are very few family studies in which all affected and
unaffected family members have been examined.17 One study in which
first-degree relatives of PD patients and controls were interviewed and
screened for tremor showed a trend toward increased risk of ET
among family members of patients with PD, with 4.8% of relatives of
PD patients having ET versus 3.5% of controls, though this did not
reach statistical significance (p 5 0.08).60 The risk increased with
younger onset of PD (5.8% of relatives had ET when PD onset was
#66 years p 5 0.006) and with tremor-dominant or mixed forms of
PD. Similar results of younger onset PD being more closely associated
with ET has also been reported in another study of 2,980 relatives of
372 PD patients;61 however, the focus of this study was on Alzheimer’s
disease, and it was not adequately powered to assess the strength of this
PD and ET relationship. In a study from Crete, where an examination
was performed on all first-degree relatives endorsing neurological
symptoms, 8.6% of first-degree relatives of 303 PD patients were noted
to have ET compared to 3.2% of controls (p 5 0.015).62 In another
study involving ET, PD, and ET–PD patients, there was a higher
occurrence of ET reported in relatives of PD patients (11.5% versus
2.8% in controls p 5 0.002) but there was no difference in the
occurrence of PD in relatives of ET patients.63 One study of 487 PD
patients, 409 controls, and 5,563 relatives found a higher incidence of
action tremor in relatives of tremor-dominant PD (6.5% p , 0.001)
than relatives of controls (3.1%) or those of patients with postural
instability and gait disorder PD (3.4%).64 In a study of 391 patients
with PD, 140 with ET, 125 with ET/PD, 99 with progressive supran-
uclear palsy (PSP), and 104 age-matched controls, a higher incidence
of family history of tremor was seen in the ET (70%), ET–PD (64%),
and PD (20.7%) populations than the PSP (11.1%) and control (10.6%)
populations.65
Several studies have examined ET and PD within large multi-
generational families. In one large family with a mixed history of ET
and PD, 11 family members had limb/head tremor that presented
early (second decade) of life. Three brothers in the family (two being
identical twins) went on to develop PD in their 50s, and on autopsy
showed cell loss in the substantia nigra and Lewy body formation
characteristic of PD.66 Another study of a multigenerational family
provided data on 138 individuals including 65 that were examined,
11 of whom were noted to have PD including six with likely coexistent
ET and PD, and an additional 19 individuals with ET.67 The presence
of multiple cases of both ET and PD in these families argues strongly
for a genetic component, while the coexistence of both conditions
within each family favor the concept of phenotypic variation of a
common gene rather than two separate genetic conditions.
Imaging
A number of different imaging modalities have demonstrated changes
in brains of ET patients suggestive of coexistent PD. In one European
study of 54 patients with ET, those demonstrating hyperechogenicity
of the substantia nigra by transcranial ultrasonography showed an
increased risk of developing PD (seven out of 18). Interestingly, nine
of the total 54 ET patients (17%) went on to develop PD (with a mean
onset of parkinsonism at 5.3 years and a mean follow-up of 6.2 years),68
a higher incidence than would be expected in the general population.
In a study involving single photon emission computed tomography
(SPECT) with 123I-ioflupane (DaTscan) imaging of 28 patients with
ET and 28 healthy controls, semi-quantitative analysis demonstrated a
reduction in striatal dopamine in the ET group (though this was not
appreciated qualitatively).69 Another DaTscan study of 32 ET patients,
47 PD patients, and 31 controls demonstrated ET patients to have
reductions in striatal dopamine uptake at intermediate levels between
PD and control patients.70 Finally, in one study, two independent
radiologists ‘‘blinded’’ to the clinical diagnosis examined 123I-ioflupane
SPECT scans in 39 ET patients (22 with isolated ET, nine with ET
and mild parkinsonism, and eight with ET–PD) and 13 healthy
controls, visually and by a semi-quantitative method.71 As expected,
ET–PD patients had the lowest striatal binding ratios, but pure ET
patients were noted to have a trend towards slightly lower striatal
binding ratios than healthy controls. However, in contrast to PD, the
dopamine transporter density was lower in the caudate nucleus rather
than the putamen, and these differences did not reach statistical
significance.
Pathology
In addition to difficulties defining ET clinically, the reports of patho-
logical examinations of the brains of patients with ET have generated
conflicting data. In contrast to studies by Rajput et al.,72,73 those
by Louis and colleagues74–78 have found pathologic features in auto-
psied brains of patients with clinically defined ET. The pathological
abnormalities in brains of patients with ET showed a reduction of
Purkinje cells (PCs), a greater incidence of PC axonal swellings
(torpedoes), and additional axonal changes.75,77 One study examining
brains of ET patients demonstrated lower climbing fiber (CF) synaptic
density, which was associated with lower numbers of PCs, and a higher
percentage of CFs in parallel fiber territory in ET patients than in
controls.74 This change was consistent across several ET ‘‘subtypes’’
including familial versus sporadic ET, and those with and without
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head tremor.76 An increase in CFs in parallel fiber territory has also
been seen in PD,78 as have PC ‘‘torpedoes.’’75 By comparison, a study
of 12 ET patients and 41 PD patients, and six controls showed no
significant difference in cerebellar PC counts between groups.72 Another
study involving 56 ET patients and 62 controls also failed to show a
significant difference in PC linear density between the two groups.79
Despite these conflicting pathologic findings, cerebellar atrophy by
volumetric analysis of magnetic resonance imaging scans has been
demonstrated in ET patients relative to PD patients and controls.80
The well-established pathologic hallmark of PD is a neuronal loss
in the substantia nigra and a widespread presence of Lewy bodies
and Lewy neurites,18 although pathologic changes in the cerebellum
and basal ganglia–cerebellum connections have been also described.81
In one study of the brains of 33 ET patients, eight (24.2%) were found
to have a substantial presence of Lewy bodies (the presence of which
were rated as moderate or severe on a semi-quantitative scale), primarily
localized to the locus ceruleus. These patients were noted to be older
than the other ET patients. In contrast, those without Lewy bodies
showed primarily cerebellar pathologic changes and were found to
have a younger age at onset of tremor, higher proportion of gait difficulty,
and family history of ET.77 A subsequent study by the same group
again demonstrated a subset of ET patients with Lewy bodies, albeit
at a lower frequency (15%).75 In contrast, another study of brains of
ET patients found no significant difference in the frequency of Lewy
bodies compared to controls, though it should be noted that the
average age of patients in this study was 86.2 years with a mean tremor
duration of 11.1 years;82 a substantially later age of onset than typical
ET. Furthermore, since the investigators excluded patients with
longstanding ET who later developed parkinsonism, this pathological
study was not suited to address the ET–PD relationship. It should also
be noted that the methodology differed between contrasting studies in
these two groups, with Lewy bodies in the former being relatively
abundant, and observed with a hematoxylin and eosin stain,77 while a
more sensitive alpha synuclein stain was used in identifying incidental
Lewy bodies in the latter group’s study.82
Genetics
Although ET is well recognized as a familial condition, the causative
gene or genes have not yet been identified. While a number of studies
have failed to identify causative gene(s),83–92 there have been some
cases in which genes appear to have an overlapping role in the risk of
developing ET and PD. LINGO1, a gene that plays a potential role in
the pathophysiology of ET,93 has been also suggested to play a role in
the pathophysiology of some cases of PD.94–96 Variants in LINGO2
have been also associated with an increased risk of developing both
ET and PD.96,97 Variants in HS1BP3, a gene that plays a role in
catecholamine and serotonin metabolism, have also been associated
both with ET and PD.98,99 One study of 571 ET patients identified a
variant in DNAJC13, found to be associated with PD, in two ET
patients (0.3%).100 This variant had previously been undetectable in a
large control population.101 A variant in the gene HTRA2, which codes
for a mitochondrial serine protease, has also been associated with both
ET and PD in one Turkish kindred.102 An allele in the non-amyloid
component of plaques (NACP)-Rep1, which serves as a promoter region
for alpha synuclein, and has a known association with an increased risk
of PD, was also shown to occur at an increased frequency in patients
with ET relative to controls.103 One study of LRRK2 variants that are
thought to be protective in the development of PD failed to demon-
strate a similar protective effect in the risk of developing ET, but did
show a trend towards a reduced incidence.104 ‘‘Functional’’ variants
have been recently identified in CACNA1G (Cav3.1) gene in three ET
families (Clark, personal communication, 2018). Although electro-
physiologic studies by whole cell patch clamp recordings in HEK293T
cells expressing the Cav3.1 mutant channels showed significant differences
in the gating of the mutant Cav3.1 channels compared to the wild-type
channel, it is not yet clear whether this variant represents a pathogenic
mutation. While the search for causative gene(s) in ET has been thus fa
unsuccessful,105 the application of new techniques may provide better
insights into the genetics of ET.
In contrast to ET, PD has traditionally been considered mostly a
sporadic disease, with cases demonstrating clear Mendelian inheri-
tance patterns representing only about 10% of PD as a whole. In
addition to the over 20 genes identified in such cases, there has
increasingly been an identification of risk factor genes, such as GBA,
LRRK2, MAPT, and SNCA in PD patients.106,107 Genetic abnormalities
found in sporadic and familial PD have been also evaluated in patients
with ET, though without an association thus far. For example, the
mutations in gene for glucocerebrosidase (GBA), recognized as a com-
mon genetic risk for PD,108,109 have not been observed in ET.110,111
Nevertheless, due to noted overlapping features, genetic research into
PD may provide new pathways and better insights into identifying the
elusive causative gene or genes in ET.
Conclusion
While a wealth of literature supports the relationship between ET
and PD (as summarized in Table 1), the association is not yet fully
defined or understood. This may be due to differences in populations
studied and the absence of a ‘‘gold standard’’ for the diagnosis of ET or
PD. Because of the clinical (and likely pathogenic) heterogeneity of ET,
future studies should consider categorizing ET into distinct subtypes
rather than simply referring to this entity as a ‘‘syndrome’’ and dividing
it into only two categories: ET and ET plus. Phenotype-specific phy-
siological, genetic, and pathological biomarkers are needed to provide
a pathogenesis-based categorization, and eventually treatment, of ET.
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